March 14, 2017 - On 9th March, IFPMA launched jointly with EFPIA and EBE a position paper entitled Considerations for physicians on switching decisions regarding biosimilars. Physician-led switching of biological medicines is a well-known medical practice. Although data on the frequency of switching in clinical practice is scarce, no evidence from clinical trials or post marketing surveillance data has found that switching to or from different biotherapeutics leads to safety concerns.
November 15, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) believes that generic and biosimilar medicines can play a fundamental role in improving access to high quality medicines for patients worldwide.
Geneva, Switzerland (June 15, 2016) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to accept the IGBA as an Assembly Member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
- Generic, Biosimilar and Value Added Medicines Industry Leaders Join Forces to Drive Access to Medicines Agenda
- IGBA commentary on FDA’s Draft Guidance on Labeling for Biosimilar Products
- IGBA welcomes Productivity Commission Draft Report in Australia and supports immediate Australian patent reform
- IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal